首页 > 最新文献

Advances in Clinical and Experimental Medicine最新文献

英文 中文
RNA binding protein ELAVL1 is associated with severity and prognosis of hepatocellular carcinoma patients: A retrospective study.
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-12 DOI: 10.17219/acem/195187
Guibao Ji, Qiuxia Guo, Langning Chen, Jingyu Chen, Zhuolin Li

Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, which is characterized by a lack of sensitive and specific biomarkers.

Objectives: This study investigates the association between ELAV-like RNA binding protein 1 (ELAVL1) and HCC patient outcomes.

Material and methods: This retrospective study encompassed 108 HCC patients who reported to Wuhan Fourth Hospital and Tongji Hospital, China, from January 2016 to August 2020. Clinical data collected included age, sex, body mass index (BMI), comorbidities, tumor-node-metastasis (TNM) stage, Barcelona Clinic Liver Cancer (BCLC) stage, and lymphatic metastasis. All patients received routine follow-up for survival and recurrence status ranged from 36 to 60 months. The serum levels of ELAVL1 were tested using enzyme-linked immuno-sorbent assay (ELISA). Levels of total bilirubin, alanine aminotransferase (ALT), aspartate transaminase (AST), HCC-related biomarkers of alpha fetoprotein (AFP), α-L-fucosidase (AFU), and carcinoembryonic antigen (CEA) were recorded.

Results: Our findings revealed a significantly higher expression of ELAVL1 in patients presenting with TNM stages III-IV, BCLC stages C-D, lymphatic metastasis, as well as deceased and recurrent patients. Receiver operating characteristic (ROC) curves showed that the areas under the curve (AUCs) for ELAVL1 in predicting mortality, recurrence and poor prognosis (defined as mortality or recurrence) in HCC patients were 0.818, 0.732 and 0.827, respectively. Patients with higher expression of ELAVL1 showed significantly higher frequencies of TNM III-IV stages, BCLC D stage, lymphatic metastasis, higher mortality, and recurrence ratio, as well as higher AFP and CEA levels. ELAVL1 was positively correlated with levels of AFP and CEA. Higher BCLC stage, lymphatic metastasis, age, AFP, and ELAVL1 were independent risk factors for poor prognosis of HCC patients.

Conclusions: Higher serum levels of ELAVL1 are associated with worse clinical outcomes and poorer prognosis in ‑HCC patients.

{"title":"RNA binding protein ELAVL1 is associated with severity and prognosis of hepatocellular carcinoma patients: A retrospective study.","authors":"Guibao Ji, Qiuxia Guo, Langning Chen, Jingyu Chen, Zhuolin Li","doi":"10.17219/acem/195187","DOIUrl":"https://doi.org/10.17219/acem/195187","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, which is characterized by a lack of sensitive and specific biomarkers.</p><p><strong>Objectives: </strong>This study investigates the association between ELAV-like RNA binding protein 1 (ELAVL1) and HCC patient outcomes.</p><p><strong>Material and methods: </strong>This retrospective study encompassed 108 HCC patients who reported to Wuhan Fourth Hospital and Tongji Hospital, China, from January 2016 to August 2020. Clinical data collected included age, sex, body mass index (BMI), comorbidities, tumor-node-metastasis (TNM) stage, Barcelona Clinic Liver Cancer (BCLC) stage, and lymphatic metastasis. All patients received routine follow-up for survival and recurrence status ranged from 36 to 60 months. The serum levels of ELAVL1 were tested using enzyme-linked immuno-sorbent assay (ELISA). Levels of total bilirubin, alanine aminotransferase (ALT), aspartate transaminase (AST), HCC-related biomarkers of alpha fetoprotein (AFP), α-L-fucosidase (AFU), and carcinoembryonic antigen (CEA) were recorded.</p><p><strong>Results: </strong>Our findings revealed a significantly higher expression of ELAVL1 in patients presenting with TNM stages III-IV, BCLC stages C-D, lymphatic metastasis, as well as deceased and recurrent patients. Receiver operating characteristic (ROC) curves showed that the areas under the curve (AUCs) for ELAVL1 in predicting mortality, recurrence and poor prognosis (defined as mortality or recurrence) in HCC patients were 0.818, 0.732 and 0.827, respectively. Patients with higher expression of ELAVL1 showed significantly higher frequencies of TNM III-IV stages, BCLC D stage, lymphatic metastasis, higher mortality, and recurrence ratio, as well as higher AFP and CEA levels. ELAVL1 was positively correlated with levels of AFP and CEA. Higher BCLC stage, lymphatic metastasis, age, AFP, and ELAVL1 were independent risk factors for poor prognosis of HCC patients.</p><p><strong>Conclusions: </strong>Higher serum levels of ELAVL1 are associated with worse clinical outcomes and poorer prognosis in ‑HCC patients.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The causal role of metabolic syndrome components in insomnia: A bidirectional two-sample Mendelian randomization.
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-12 DOI: 10.17219/acem/195188
Lingxin Liao, Jun Zhou, Xinyue Zhang, Yihui Zhu

Background: The neuroendocrine system's role in maintaining bodily homeostasis implicates it in insomnia, suggesting both causal relationships and therapeutic targets. Yet, studies examining the link between metabolic syndrome (MetS) components such as hypertension, elevated blood glucose levels and abnormal cholesterol and insomnia have been inconsistent. Some research suggests a correlation, proposing that metabolic dysfunctions might contribute to sleep disturbances. However, other studies found little to no significant connection, indicating the complexity of this relationship and the potential influence of genetic, lifestyle and environmental factors. These contradictory findings underscore the challenges in fully understanding the intricate interplay between metabolic health and sleep quality.

Objectives: To explore the relationship between MetS and insomnia.

Material and methods: This study used bidirectional two-sample Mendelian randomization (MR) analysis to determine the causal relationship between the characteristics of MetS components and insomnia. Based on Genome-Wide Association Studies (GWAS) public databases, we explored the causal relationship between waist circumference (WC), hypertension, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), and the risk of insomnia. Sensitivity analysis was conducted to evaluate the stability, heterogeneity and potential presence of horizontal pleiotropy in the results.

Results: Waist circumference and hypertension were associated with an increased risk of insomnia (WC, odds ratio (OR) = 1.05, 95% confidence interval (95% CI): 1.03-1.06, p = 9.15e-07; hypertension, OR = 1.06, 95% CI: 1.02-1.10, p = 0.005). In the reverse MR analysis, there was no significant causal relationship between insomnia and WC, TG, HDL-C, and FBG.

Conclusions: Our study has demonstrated the close connection between MetS components and insomnia by genetic means, thereby guiding the future research direction of insomnia prevention and treatment.

{"title":"The causal role of metabolic syndrome components in insomnia: A bidirectional two-sample Mendelian randomization.","authors":"Lingxin Liao, Jun Zhou, Xinyue Zhang, Yihui Zhu","doi":"10.17219/acem/195188","DOIUrl":"https://doi.org/10.17219/acem/195188","url":null,"abstract":"<p><strong>Background: </strong>The neuroendocrine system's role in maintaining bodily homeostasis implicates it in insomnia, suggesting both causal relationships and therapeutic targets. Yet, studies examining the link between metabolic syndrome (MetS) components such as hypertension, elevated blood glucose levels and abnormal cholesterol and insomnia have been inconsistent. Some research suggests a correlation, proposing that metabolic dysfunctions might contribute to sleep disturbances. However, other studies found little to no significant connection, indicating the complexity of this relationship and the potential influence of genetic, lifestyle and environmental factors. These contradictory findings underscore the challenges in fully understanding the intricate interplay between metabolic health and sleep quality.</p><p><strong>Objectives: </strong>To explore the relationship between MetS and insomnia.</p><p><strong>Material and methods: </strong>This study used bidirectional two-sample Mendelian randomization (MR) analysis to determine the causal relationship between the characteristics of MetS components and insomnia. Based on Genome-Wide Association Studies (GWAS) public databases, we explored the causal relationship between waist circumference (WC), hypertension, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), and the risk of insomnia. Sensitivity analysis was conducted to evaluate the stability, heterogeneity and potential presence of horizontal pleiotropy in the results.</p><p><strong>Results: </strong>Waist circumference and hypertension were associated with an increased risk of insomnia (WC, odds ratio (OR) = 1.05, 95% confidence interval (95% CI): 1.03-1.06, p = 9.15e-07; hypertension, OR = 1.06, 95% CI: 1.02-1.10, p = 0.005). In the reverse MR analysis, there was no significant causal relationship between insomnia and WC, TG, HDL-C, and FBG.</p><p><strong>Conclusions: </strong>Our study has demonstrated the close connection between MetS components and insomnia by genetic means, thereby guiding the future research direction of insomnia prevention and treatment.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving sepsis mortality prediction with machine learning: A comparative study of advanced classifiers and performance metrics.
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-11 DOI: 10.17219/acem/194660
Puyu Zhou, Jiazheng Duan, Jianqing Li

Background: High sepsis mortality rates pose a serious global health problem. Machine learning is a promising technique with the potential to improve mortality prediction for this disease in an accurate and timely manner.

Objectives: This study aimed to develop a model capable of rapidly and accurately predicting sepsis mortality using data that can be quickly obtained in an ambulance, with a focus on practical application during ambulance transport.

Material and methods: Data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) dataset were used to compare the performance of 11 machine learning algorithms against the widely utilized quick Sequential Organ Failure Assessment (qSOFA) score. A dynamic updating model was implemented. Performance was evaluated using area under the curve (AUC) and precision-recall area under the curve (PRAUC) scores, and feature importance was assessed with SHapley Additive exPlanations (SHAP) values.

Results: The light gradient boosting machine (LightGBM) model achieved the highest AUC (0.79) and PRAUC (0.44) scores, outperforming the qSOFA score (AUC = 0.76, PRAUC = 0.40). The LightGBM also achieved the highest PRAUC (0.44), followed by Optuna_LightGBM (0.43) and random forest (0.42). The dynamically updated and tuned model further improved performance metrics (AUC = 0.79, PRAUC = 0.44) compared to the base model (AUC = 0.76, PRAUC = 0.39). Feature importance analysis offers clinicians insights for prioritizing patient assessments and interventions.

Conclusions: The LightGBM-based model demonstrated superior performance in predicting sepsis-related mortality in an ambulance setting. This study underscores the practical applicability of machine learning models, addressing the limitations of previous research, and highlights the importance of real-time updates and hyperparameter tuning in optimizing model performance.

{"title":"Improving sepsis mortality prediction with machine learning: A comparative study of advanced classifiers and performance metrics.","authors":"Puyu Zhou, Jiazheng Duan, Jianqing Li","doi":"10.17219/acem/194660","DOIUrl":"https://doi.org/10.17219/acem/194660","url":null,"abstract":"<p><strong>Background: </strong>High sepsis mortality rates pose a serious global health problem. Machine learning is a promising technique with the potential to improve mortality prediction for this disease in an accurate and timely manner.</p><p><strong>Objectives: </strong>This study aimed to develop a model capable of rapidly and accurately predicting sepsis mortality using data that can be quickly obtained in an ambulance, with a focus on practical application during ambulance transport.</p><p><strong>Material and methods: </strong>Data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) dataset were used to compare the performance of 11 machine learning algorithms against the widely utilized quick Sequential Organ Failure Assessment (qSOFA) score. A dynamic updating model was implemented. Performance was evaluated using area under the curve (AUC) and precision-recall area under the curve (PRAUC) scores, and feature importance was assessed with SHapley Additive exPlanations (SHAP) values.</p><p><strong>Results: </strong>The light gradient boosting machine (LightGBM) model achieved the highest AUC (0.79) and PRAUC (0.44) scores, outperforming the qSOFA score (AUC = 0.76, PRAUC = 0.40). The LightGBM also achieved the highest PRAUC (0.44), followed by Optuna_LightGBM (0.43) and random forest (0.42). The dynamically updated and tuned model further improved performance metrics (AUC = 0.79, PRAUC = 0.44) compared to the base model (AUC = 0.76, PRAUC = 0.39). Feature importance analysis offers clinicians insights for prioritizing patient assessments and interventions.</p><p><strong>Conclusions: </strong>The LightGBM-based model demonstrated superior performance in predicting sepsis-related mortality in an ambulance setting. This study underscores the practical applicability of machine learning models, addressing the limitations of previous research, and highlights the importance of real-time updates and hyperparameter tuning in optimizing model performance.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examination of 6 and 12 month follow-up of calcium hydroxide and calcium silicate materials used in direct and indirect pulp capping.
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-11 DOI: 10.17219/acem/194504
Yasemin Yavuz, Sedef Kotanli, Mehmet S Dogan, Zelal Almak

Background: Pulpal vitality is important for the tooth to maintain its physiological function and preserve its structure.

Objectives: The aim of this study was to evaluate the clinical and radiographic 6- and 12-month treatment success of calcium hydroxide (CH) and calcium silicate materials in indirect pulp treatment (IPT) and direct pulp capping (DPC) in teeth with deep dentin decay.

Material and methods: The study included 143 teeth of patients aged 17-69 years with no systemic disease. The study is grouped under 3 main groups (Dycal, Biodentine, TheraCal PT). Direct pulp capping was applied to 65 teeth and IPT to 66 teeth. All teeth were restored with Universal adhesive system and Universal composite (G-Premio Bond; GC Corp., Tokyo, Japan).

Results: In the statistical evaluations of the data obtained, 0.05 was accepted as the level of statistical significance. The general success rate in the IPT group was found to be 95.2% for Biodentine (Septodont, SaintMaur-des-Fossés, France), 91.7% for Dycal (Dentsply/Caulk, International Inc. Milford, USA) and 90.1% for TheraCal PT (Bisco Inc., Schaumburg, USA) at both 6 and 12 months. When the clinical and radiographic success was compared at 6 months and 12 months, no statistically significant difference was determined between the materials (p > 0.05). In the clinical and radiographic evaluations at the end of 6-month follow-up in the DPC group, the success rates were determined to be 96.0% for Biodentine, 81.8% for Dycal and 63.2% for TheraCal PT. At 12 months, these rates were 96.0% for Biodentine, 68.2% for Dycal and 63.2% for TheraCal PT. DPC Biodentine was found to be the most successful material (96.0%).

Conclusions: At the end of the 12-month follow-up period, it was considered that the 3 materials (Biodentine, Dycal, TheraCal) can be selected for IPT. In DPC, Biodentine was found to be more successful than both calcium silicate containing resin and CH.

{"title":"Examination of 6 and 12 month follow-up of calcium hydroxide and calcium silicate materials used in direct and indirect pulp capping.","authors":"Yasemin Yavuz, Sedef Kotanli, Mehmet S Dogan, Zelal Almak","doi":"10.17219/acem/194504","DOIUrl":"https://doi.org/10.17219/acem/194504","url":null,"abstract":"<p><strong>Background: </strong>Pulpal vitality is important for the tooth to maintain its physiological function and preserve its structure.</p><p><strong>Objectives: </strong>The aim of this study was to evaluate the clinical and radiographic 6- and 12-month treatment success of calcium hydroxide (CH) and calcium silicate materials in indirect pulp treatment (IPT) and direct pulp capping (DPC) in teeth with deep dentin decay.</p><p><strong>Material and methods: </strong>The study included 143 teeth of patients aged 17-69 years with no systemic disease. The study is grouped under 3 main groups (Dycal, Biodentine, TheraCal PT). Direct pulp capping was applied to 65 teeth and IPT to 66 teeth. All teeth were restored with Universal adhesive system and Universal composite (G-Premio Bond; GC Corp., Tokyo, Japan).</p><p><strong>Results: </strong>In the statistical evaluations of the data obtained, 0.05 was accepted as the level of statistical significance. The general success rate in the IPT group was found to be 95.2% for Biodentine (Septodont, SaintMaur-des-Fossés, France), 91.7% for Dycal (Dentsply/Caulk, International Inc. Milford, USA) and 90.1% for TheraCal PT (Bisco Inc., Schaumburg, USA) at both 6 and 12 months. When the clinical and radiographic success was compared at 6 months and 12 months, no statistically significant difference was determined between the materials (p > 0.05). In the clinical and radiographic evaluations at the end of 6-month follow-up in the DPC group, the success rates were determined to be 96.0% for Biodentine, 81.8% for Dycal and 63.2% for TheraCal PT. At 12 months, these rates were 96.0% for Biodentine, 68.2% for Dycal and 63.2% for TheraCal PT. DPC Biodentine was found to be the most successful material (96.0%).</p><p><strong>Conclusions: </strong>At the end of the 12-month follow-up period, it was considered that the 3 materials (Biodentine, Dycal, TheraCal) can be selected for IPT. In DPC, Biodentine was found to be more successful than both calcium silicate containing resin and CH.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Squamous and basal skin cancers in 17,207 solid organ transplant recipients: Real-world data from national health insurance database in Poland.
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-06 DOI: 10.17219/acem/199653
Wojciech M Wysocki, Aleksandra Kulbat, Karolina Richter, Marta Krzysztofik, Marta Kołodziej-Rzepa, Tomasz Wojewoda

Background: Immunosuppressive therapy in organ transplant ensures proper graft function for many years, but it is burdened with a negative impact on the development of skin cancer in them.

Objectives: To characterize the impact of immunosuppressive therapy in transplant recipients on the development of non-melanoma skin cancers (NMSC).

Material and methods: A total of 17,207 Polish patients who underwent liver, heart or kidney transplants between 2010 and 2022 and were on immunosuppression were included in the study. Immunosuppression was most commonly achieved using a regimen of tacrolimus (TAC) or cyclosporine A (CsA) combined with mycophenolic acid (MPA) and glucocorticosteroids (GS). Data on NMSC incidence from the National Health Fund in this population were analyzed and compared against incidence of NMSC in general Polish population in the same period.

Results: Renal transplant recipients demonstrated a significantly elevated risk of NMSC compared to the general population, with a 1-year cumulative incidence of 0.09% vs 0.04% (p < 0.001), a 5-year incidence of 1.21% vs 0.18% (p < 0.001) and a 10-year incidence of 4.18% vs 0.36% (p < 0.001). Liver transplant recipients exhibited an elevated risk for the development of NMSC, which persisted and increased over time (incidence of 0.09% vs 0.04% at 1 year (p < 0.001), 0.83% vs 0.18% at 5 years (p < 0.001) and 2.65% vs 0.36% at 10 years (p < 0.001)). Heart transplant recipients also showed a significantly higher cumulative incidence of NMSC at 1 year (0.09% vs 0.04%, p < 0.001), 5 years (0.89% vs 0.18%, p < 0.001) and 10 years (4.06% vs. 0.36%, p < 0.001) post-transplantation.

Conclusions: Organ transplant recipients have an 2 times at 1 year, 4,5 times after 5 years and 9 times after 10 years increased risk of NMSC on average as opposed to general Polish population in the same period.

{"title":"Squamous and basal skin cancers in 17,207 solid organ transplant recipients: Real-world data from national health insurance database in Poland.","authors":"Wojciech M Wysocki, Aleksandra Kulbat, Karolina Richter, Marta Krzysztofik, Marta Kołodziej-Rzepa, Tomasz Wojewoda","doi":"10.17219/acem/199653","DOIUrl":"https://doi.org/10.17219/acem/199653","url":null,"abstract":"<p><strong>Background: </strong>Immunosuppressive therapy in organ transplant ensures proper graft function for many years, but it is burdened with a negative impact on the development of skin cancer in them.</p><p><strong>Objectives: </strong>To characterize the impact of immunosuppressive therapy in transplant recipients on the development of non-melanoma skin cancers (NMSC).</p><p><strong>Material and methods: </strong>A total of 17,207 Polish patients who underwent liver, heart or kidney transplants between 2010 and 2022 and were on immunosuppression were included in the study. Immunosuppression was most commonly achieved using a regimen of tacrolimus (TAC) or cyclosporine A (CsA) combined with mycophenolic acid (MPA) and glucocorticosteroids (GS). Data on NMSC incidence from the National Health Fund in this population were analyzed and compared against incidence of NMSC in general Polish population in the same period.</p><p><strong>Results: </strong>Renal transplant recipients demonstrated a significantly elevated risk of NMSC compared to the general population, with a 1-year cumulative incidence of 0.09% vs 0.04% (p < 0.001), a 5-year incidence of 1.21% vs 0.18% (p < 0.001) and a 10-year incidence of 4.18% vs 0.36% (p < 0.001). Liver transplant recipients exhibited an elevated risk for the development of NMSC, which persisted and increased over time (incidence of 0.09% vs 0.04% at 1 year (p < 0.001), 0.83% vs 0.18% at 5 years (p < 0.001) and 2.65% vs 0.36% at 10 years (p < 0.001)). Heart transplant recipients also showed a significantly higher cumulative incidence of NMSC at 1 year (0.09% vs 0.04%, p < 0.001), 5 years (0.89% vs 0.18%, p < 0.001) and 10 years (4.06% vs. 0.36%, p < 0.001) post-transplantation.</p><p><strong>Conclusions: </strong>Organ transplant recipients have an 2 times at 1 year, 4,5 times after 5 years and 9 times after 10 years increased risk of NMSC on average as opposed to general Polish population in the same period.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which risk factors are involved in a distal biceps tendon injury? A systematic review. 肱二头肌远端肌腱损伤涉及哪些风险因素?系统综述。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-01 DOI: 10.17219/acem/187891
Markus Jaschke, Łukasz Kołodziej, Aleksandra Wilk, Marek Droździk

Distal biceps tendon rupture is a rare injury predominately occurring in middle-aged men. This study aimed to collect relevant risk factors associated with distal biceps tendon rupture from the published literature. This systematic review aimed to collect and tabulate the risk factors for distal biceps tendon rupture. Studies published in English were searched concerning risk factors for distal biceps tendon ruptures until July 2022; cohort studies, case series and randomized controlled trials were subjected to analysis. Case studies, cadaveric studies and reviews in any form were excluded. The studies were quantitatively and qualitatively reviewed. One hundred twenty-one articles presenting risk factors for distal biceps tendon ruptures were identified, recruiting a total of 7,484-7,576 patients. The average age of the individuals was 46.8 years, with 96.7% being males and 94.7% having affinity for sports activities. In 56.7% of the cases, the dominant arm was involved, and in 54.6%, the right arm was affected. The use of tobacco was found in 20.8% of cases and of anabolic steroids in 2.5% of cases. On average, 55.8% of distal biceps tendon rupture patients had a physical occupation and the most common mechanism of the injury was related to heavy weight lifting observed in 53.2% of subjects. The most common and outstanding reported risk factors for distal biceps tendon ruptures were age, sex and sports activity, i.e., middle-aged males being still physically active and practicing sports. Steroid usage does not seem to increase significantly the risk of the distal biceps tendon rupture.

肱二头肌远端肌腱断裂是一种罕见的损伤,主要发生在中年男性身上。本研究旨在从已发表的文献中收集与肱二头肌远端肌腱断裂相关的风险因素。本系统性综述旨在收集肱二头肌远端肌腱断裂的风险因素并制成表格。检索了截至 2022 年 7 月发表的有关肱二头肌远端肌腱断裂风险因素的英文研究;对队列研究、病例系列研究和随机对照试验进行了分析。病例研究、尸体研究和任何形式的综述均被排除在外。对这些研究进行了定量和定性审查。共发现了121篇介绍肱二头肌远端肌腱断裂风险因素的文章,招募了7484-7576名患者。这些患者的平均年龄为 46.8 岁,96.7% 为男性,94.7% 有体育运动爱好。在 56.7% 的病例中,优势臂受累,54.6% 的病例右臂受累。20.8%的病例使用烟草,2.5%的病例使用合成类固醇。平均而言,55.8%的肱二头肌远端肌腱断裂患者从事体力劳动,53.2%的患者最常见的受伤机制与举重有关。据报道,肱二头肌远端肌腱断裂最常见和最突出的风险因素是年龄、性别和体育活动,即中年男性仍在从事体育活动和体育锻炼。使用类固醇似乎不会显著增加肱二头肌远端肌腱断裂的风险。
{"title":"Which risk factors are involved in a distal biceps tendon injury? A systematic review.","authors":"Markus Jaschke, Łukasz Kołodziej, Aleksandra Wilk, Marek Droździk","doi":"10.17219/acem/187891","DOIUrl":"10.17219/acem/187891","url":null,"abstract":"<p><p>Distal biceps tendon rupture is a rare injury predominately occurring in middle-aged men. This study aimed to collect relevant risk factors associated with distal biceps tendon rupture from the published literature. This systematic review aimed to collect and tabulate the risk factors for distal biceps tendon rupture. Studies published in English were searched concerning risk factors for distal biceps tendon ruptures until July 2022; cohort studies, case series and randomized controlled trials were subjected to analysis. Case studies, cadaveric studies and reviews in any form were excluded. The studies were quantitatively and qualitatively reviewed. One hundred twenty-one articles presenting risk factors for distal biceps tendon ruptures were identified, recruiting a total of 7,484-7,576 patients. The average age of the individuals was 46.8 years, with 96.7% being males and 94.7% having affinity for sports activities. In 56.7% of the cases, the dominant arm was involved, and in 54.6%, the right arm was affected. The use of tobacco was found in 20.8% of cases and of anabolic steroids in 2.5% of cases. On average, 55.8% of distal biceps tendon rupture patients had a physical occupation and the most common mechanism of the injury was related to heavy weight lifting observed in 53.2% of subjects. The most common and outstanding reported risk factors for distal biceps tendon ruptures were age, sex and sports activity, i.e., middle-aged males being still physically active and practicing sports. Steroid usage does not seem to increase significantly the risk of the distal biceps tendon rupture.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"257-268"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Withania somnifera and Trigonella foenum-graecum as ingredients of testosterone-boosting supplements: Possible clinical implications. 将睡茄(Withania somnifera)和川芎(Trigonella foenum-graecum)作为睾酮促进剂的成分:可能的临床意义。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-01 DOI: 10.17219/acem/185743
Monika Skrzypiec-Spring, Andrzej Pokrywka, Justyna Kuliczkowska-Płaksej, Adam Szeląg, Marek Bolanowski

This narrative review provides an overview of scientific studies on dietary supplements that may affect circulating testosterone (T) levels to explore which substances are scientifically proven to increase T concentration. We also review the scientific literature for their potential mechanisms and laboratory test changes triggered by their use. Based on the analysis of existing data on substances used to increase endogenous T levels, especially double-blind placebo-controlled randomized clinical trials, we selected 2 herbal extracts with the best documented positive effects on T levels, Withania somnifera root and root extracts/leaves and seed extracts of Trigonella foenum-graecum. Although these substances have different postulated mechanisms of action, both significantly increase T levels in men. Withania somnifera may inhibit the effects of cortisol and prolactin on the hypothalamic-pituitary-gonadal axis and directly affect the hypothalamus. Trigonella foenum-graecum seeds contain the active substance diosgenin, which is a precursor for sex hormone synthesis in gonads.

本叙述性综述概述了有关可能影响循环睾酮(T)水平的膳食补充剂的科学研究,以探讨哪些物质经科学证实可提高睾酮浓度。我们还回顾了有关这些物质的潜在机制以及使用这些物质所引发的实验室测试变化的科学文献。根据对用于提高内源性 T 水平的物质的现有数据,特别是双盲安慰剂对照随机临床试验的分析,我们选择了两种对 T 水平具有最佳积极作用的草药提取物,即睡茄(Withania somnifera)的根和根提取物/叶,以及川芎(Trigonella foenum-graecum)的种子提取物。虽然这两种物质的作用机制不同,但它们都能显著提高男性的 T 水平。睡茄可抑制皮质醇和催乳素对下丘脑-垂体-性腺轴的影响,并直接影响下丘脑。Trigonella foenum-graecum 种子含有活性物质 diosgenin,这是性腺合成性激素的前体。
{"title":"Withania somnifera and Trigonella foenum-graecum as ingredients of testosterone-boosting supplements: Possible clinical implications.","authors":"Monika Skrzypiec-Spring, Andrzej Pokrywka, Justyna Kuliczkowska-Płaksej, Adam Szeląg, Marek Bolanowski","doi":"10.17219/acem/185743","DOIUrl":"10.17219/acem/185743","url":null,"abstract":"<p><p>This narrative review provides an overview of scientific studies on dietary supplements that may affect circulating testosterone (T) levels to explore which substances are scientifically proven to increase T concentration. We also review the scientific literature for their potential mechanisms and laboratory test changes triggered by their use. Based on the analysis of existing data on substances used to increase endogenous T levels, especially double-blind placebo-controlled randomized clinical trials, we selected 2 herbal extracts with the best documented positive effects on T levels, Withania somnifera root and root extracts/leaves and seed extracts of Trigonella foenum-graecum. Although these substances have different postulated mechanisms of action, both significantly increase T levels in men. Withania somnifera may inhibit the effects of cortisol and prolactin on the hypothalamic-pituitary-gonadal axis and directly affect the hypothalamus. Trigonella foenum-graecum seeds contain the active substance diosgenin, which is a precursor for sex hormone synthesis in gonads.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"295-303"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140846824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence-based healthcare: Bridging the gap between research and practice.
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-01 DOI: 10.17219/acem/201184
Aleksandra Królikowska, Robert Prill, Miloslav Klugar

The establishment of the first JBI Affiliated group in Poland at Wroclaw Medical University marks a significant advancement in evidence-based healthcare (EBHC) nationally. This editorial explores the evolution of EBHC and the critical role of JBI in driving its progress. Founded in 1996 as a research institute at the Royal Adelaide Hospital in South Australia and now based at the University of Adelaide, JBI has emerged as an international leader in evidence synthesis, transfer and implementation. Its Feasibility, Appropriateness, Meaningfulness, and Effectiveness (FAME) framework highlights the feasibility, appropriateness, meaningfulness, and effectiveness of healthcare practices, ensuring that decisions are patient-centered and contextually relevant. JBI's global collaboration network encompasses over 85 entities, with 23 located in Europe, emphasizing the importance of cultural inclusivity and international partnerships. Recent initiatives include translating the JBI Model of into Polish, German and Czech, linking global knowledge to local contexts, and enhancing understanding for professionals and students alike. This editorial also underscores the collaborative achievements of JBI entities in Wroclaw, Brandenburg an der Havel, Prague, and Olomouc. These partnerships have propelled regional implementation, research and education, fostering a shared vision for elevating healthcare quality. Launching a new EBHC section in the Advances in Clinical and Experimental Medicine journal is a significant step forward, inviting global contributions and stimulating innovation and knowledge sharing in EBHC. The presence of a JBI Affiliated group at Wroclaw Medical University symbolizes a transformative commitment to excellence and collaboration. It sets new benchmarks for healthcare in Poland and beyond while reinforcing the global mission of evidence-based practice.

{"title":"Evidence-based healthcare: Bridging the gap between research and practice.","authors":"Aleksandra Królikowska, Robert Prill, Miloslav Klugar","doi":"10.17219/acem/201184","DOIUrl":"10.17219/acem/201184","url":null,"abstract":"<p><p>The establishment of the first JBI Affiliated group in Poland at Wroclaw Medical University marks a significant advancement in evidence-based healthcare (EBHC) nationally. This editorial explores the evolution of EBHC and the critical role of JBI in driving its progress. Founded in 1996 as a research institute at the Royal Adelaide Hospital in South Australia and now based at the University of Adelaide, JBI has emerged as an international leader in evidence synthesis, transfer and implementation. Its Feasibility, Appropriateness, Meaningfulness, and Effectiveness (FAME) framework highlights the feasibility, appropriateness, meaningfulness, and effectiveness of healthcare practices, ensuring that decisions are patient-centered and contextually relevant. JBI's global collaboration network encompasses over 85 entities, with 23 located in Europe, emphasizing the importance of cultural inclusivity and international partnerships. Recent initiatives include translating the JBI Model of into Polish, German and Czech, linking global knowledge to local contexts, and enhancing understanding for professionals and students alike. This editorial also underscores the collaborative achievements of JBI entities in Wroclaw, Brandenburg an der Havel, Prague, and Olomouc. These partnerships have propelled regional implementation, research and education, fostering a shared vision for elevating healthcare quality. Launching a new EBHC section in the Advances in Clinical and Experimental Medicine journal is a significant step forward, inviting global contributions and stimulating innovation and knowledge sharing in EBHC. The presence of a JBI Affiliated group at Wroclaw Medical University symbolizes a transformative commitment to excellence and collaboration. It sets new benchmarks for healthcare in Poland and beyond while reinforcing the global mission of evidence-based practice.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"139-147"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An update on cardiovascular disorders in systemic lupus erythematosus. 系统性红斑狼疮心血管疾病的最新进展。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-01 DOI: 10.17219/acem/184868
Ewa Pędzich, Adrian Bednarek, Julita Młynarska, Emilia Włoszek, Dominika Klimczak-Tomaniak, Karolina Gumiężna, Adam Piasecki, Adam Rdzanek, Grażyna Sygitowicz, Marcin Grabowski, Mariusz Tomaniak

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a complex multifactorial etiology that develops as a result of autoimmune processes, leading to widespread inflammation and malfunction of multiple tissues and organs, and, as a consequence, triggers arterial hypertension, conduction disorders, valvular heart disease, pulmonary hypertension (PH), and venous thromboembolism events (VTE), contributing to increased mortality. Moreover, autoimmune abnormalities can accelerate atherogenesis and lead to many SLE manifestations, including coronary artery disease (CAD) and cerebrovascular events. The current review aimed to systematize existing data from the latest works and summarize published guidelines and recommendations. In particular, the prevalence of cardiovascular disorders in SLE patients, advances in diagnostics (including imaging methods and biomarker laboratory testing), the possible future direction of therapy, and the latest European Alliance of Associations for Rheumatology (EULAR) guidelines for optimal management of cardiovascular risk in SLE were overviewed.

系统性红斑狼疮(SLE)是一种慢性自身免疫性疾病,具有复杂的多因素病因,是自身免疫过程的结果,会导致广泛的炎症和多个组织器官功能失调,从而引发动脉高血压、传导障碍、瓣膜性心脏病、肺动脉高压(PH)和静脉血栓栓塞事件(VTE),导致死亡率增加。此外,自身免疫异常可加速动脉粥样硬化的发生,并导致许多系统性红斑狼疮表现,包括冠状动脉疾病(CAD)和脑血管事件。本次综述旨在系统整理最新著作中的现有数据,并总结已发表的指南和建议。特别是概述了系统性红斑狼疮患者心血管疾病的发病率、诊断学的进展(包括成像方法和生物标志物实验室检测)、未来可能的治疗方向,以及欧洲风湿病学协会联盟(EULAR)关于系统性红斑狼疮心血管风险优化管理的最新指南。
{"title":"An update on cardiovascular disorders in systemic lupus erythematosus.","authors":"Ewa Pędzich, Adrian Bednarek, Julita Młynarska, Emilia Włoszek, Dominika Klimczak-Tomaniak, Karolina Gumiężna, Adam Piasecki, Adam Rdzanek, Grażyna Sygitowicz, Marcin Grabowski, Mariusz Tomaniak","doi":"10.17219/acem/184868","DOIUrl":"10.17219/acem/184868","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a complex multifactorial etiology that develops as a result of autoimmune processes, leading to widespread inflammation and malfunction of multiple tissues and organs, and, as a consequence, triggers arterial hypertension, conduction disorders, valvular heart disease, pulmonary hypertension (PH), and venous thromboembolism events (VTE), contributing to increased mortality. Moreover, autoimmune abnormalities can accelerate atherogenesis and lead to many SLE manifestations, including coronary artery disease (CAD) and cerebrovascular events. The current review aimed to systematize existing data from the latest works and summarize published guidelines and recommendations. In particular, the prevalence of cardiovascular disorders in SLE patients, advances in diagnostics (including imaging methods and biomarker laboratory testing), the possible future direction of therapy, and the latest European Alliance of Associations for Rheumatology (EULAR) guidelines for optimal management of cardiovascular risk in SLE were overviewed.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"269-281"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140100768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum fibroblast growth factor 19 level correlates inversely with clinical and endoscopic activity of inflammatory bowel disease. 血清成纤维细胞生长因子 19 水平与炎症性肠病的临床和内窥镜活动性成反比。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-02-01 DOI: 10.17219/acem/184132
Agata Łukawska, Agata Mulak

Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic condition with relapsing-remitting course. Diarrhea and abdominal pain are the most common IBD symptoms. Fibroblast growth factor 19 (FGF19) is an endocrine factor that inhibits hepatic bile acid production and may be used as a diagnostic marker for bile acid malabsorption.

Objectives: To assess serum FGF19 levels in active and inactive phases of IBD and find a potential correlation between FGF19 and disease activity.

Material and methods: Fasting serum FGF19 levels were measured in 105 IBD patients (47 UC patients, 41 CD patients without previous ileocecal resection (NR-CD), 17 CD patients after ileocecal resection (IR-CD), and 17 control subjects). The disease activity was assessed using clinical, laboratory and endoscopic criteria.

Results: Inverse correlations were found between FGF19 level and intensity of diarrhea (in UC), abdominal pain intensity (in UC and IR-CD) and inflammatory markers (in UC and IR-CD). Moreover, FGF19 concentration was inversely correlated with clinical and endoscopic activity indices in UC and CD.

Conclusions: Fluctuations in FGF19 level related to clinical and endoscopic activity of UC and CD revealed a clear pattern of higher values in remission than in active disease phases. Fibroblast growth factor 19 may serve as a potential diagnostic biomarker and constitute a new therapeutic target in IBD.

背景:炎症性肠病(IBD),包括溃疡性结肠炎(UC)和克罗恩病(CD),是一种慢性病,病程为复发-缓解。腹泻和腹痛是最常见的 IBD 症状。成纤维细胞生长因子 19(FGF19)是一种抑制肝脏胆汁酸生成的内分泌因子,可作为胆汁酸吸收不良的诊断标志物:评估IBD活动期和非活动期的血清FGF19水平,并发现FGF19与疾病活动之间的潜在相关性:对105名IBD患者(47名UC患者、41名既往未行回盲部切除术(NR-CD)的CD患者、17名行回盲部切除术(IR-CD)的CD患者和17名对照组受试者)的空腹血清FGF19水平进行了测定。疾病活动性采用临床、实验室和内窥镜标准进行评估:结果:发现FGF19水平与腹泻强度(UC)、腹痛强度(UC和IR-CD)和炎症指标(UC和IR-CD)呈反向相关。此外,在 UC 和 CD 中,FGF19 浓度与临床和内窥镜活动指数呈反比:结论:纤维母细胞生长因子19水平的波动与UC和CD的临床和内镜活动相关,显示出缓解期的数值高于疾病活动期的数值的明显模式。成纤维细胞生长因子19可作为一种潜在的诊断生物标志物,并成为IBD的新治疗靶点。
{"title":"Serum fibroblast growth factor 19 level correlates inversely with clinical and endoscopic activity of inflammatory bowel disease.","authors":"Agata Łukawska, Agata Mulak","doi":"10.17219/acem/184132","DOIUrl":"10.17219/acem/184132","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic condition with relapsing-remitting course. Diarrhea and abdominal pain are the most common IBD symptoms. Fibroblast growth factor 19 (FGF19) is an endocrine factor that inhibits hepatic bile acid production and may be used as a diagnostic marker for bile acid malabsorption.</p><p><strong>Objectives: </strong>To assess serum FGF19 levels in active and inactive phases of IBD and find a potential correlation between FGF19 and disease activity.</p><p><strong>Material and methods: </strong>Fasting serum FGF19 levels were measured in 105 IBD patients (47 UC patients, 41 CD patients without previous ileocecal resection (NR-CD), 17 CD patients after ileocecal resection (IR-CD), and 17 control subjects). The disease activity was assessed using clinical, laboratory and endoscopic criteria.</p><p><strong>Results: </strong>Inverse correlations were found between FGF19 level and intensity of diarrhea (in UC), abdominal pain intensity (in UC and IR-CD) and inflammatory markers (in UC and IR-CD). Moreover, FGF19 concentration was inversely correlated with clinical and endoscopic activity indices in UC and CD.</p><p><strong>Conclusions: </strong>Fluctuations in FGF19 level related to clinical and endoscopic activity of UC and CD revealed a clear pattern of higher values in remission than in active disease phases. Fibroblast growth factor 19 may serve as a potential diagnostic biomarker and constitute a new therapeutic target in IBD.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"187-198"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in Clinical and Experimental Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1